Ticker Details
TG Therapeutics, Inc. TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development & commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
IPO Date:	June 1, 2010
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.31B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.54 | 3.42%
Avg Daily Range (30 D):	$1.49 | 2.83%
Avg Daily Range (90 D):	$1.26 | 2.72%

Institutional Daily Volume
Avg Daily Volume:	1.66M
Avg Daily Volume (30 D):	1.79M
Avg Daily Volume (90 D):	1.85M

Trade Size
Avg Trade Size (Sh.):	113
Avg Trade Size (Sh.) (30 D):	66
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	6,387
Avg Institutional Trade:	$3.07M
Avg Institutional Trade (30 D):	$5.2M
Avg Institutional Trade (90 D):	$5.53M
Avg Institutional Trade Volume:	.14M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.82M
Avg Closing Trade (30 D):	$19.16M
Avg Closing Trade (90 D):	$20.14M
Avg Closing Volume:	270.98K

News

Jul 17, 2026 @ 1:25 AM Kuehn Law Encourages Investors of TG Therapeutics,... Source: Kuehn Law, Pllc

Feb 8, 2026 @ 9:17 PM TG Therapeutics Announces Collaboration with Chris... Source: Tg Therapeutics, Inc.

Jan 14, 2026 @ 1:36 PM Stock Market Today: S&P 500, Dow Jones, Nasdaq 100... Source: Rishabh Mishra

Nov 10, 2025 @ 9:00 PM TG Therapeutics to Participate in the TD Cowen Imm... Source: Tg Therapeutics, Inc.

Aug 4, 2025 @ 4:23 PM TG Therapeutics Q2 Revenue Up 91% Source: Jesterai

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.05	$.14	$.2
Diluted EPS	$.05	$.12	$.15
Revenue	$240.34M	$204.92M	$192.57M
Gross Profit	$199.14M	$171.41M	$154.43M
Net Income / Loss	$7.78M	$19.78M	$23.04M
Operating Income / Loss	$21.67M	$34.8M	$50.49M
Cost of Revenue	$41.19M	$33.51M	$38.14M
Net Cash Flow	$40.38M	$363.07M	$5.08M
PE Ratio

Splits
Apr 30, 2012	5:281
Jul 14, 2011	1:50
Sep 25, 2003	1:5